Genomic insights into the 2022–2023Vibrio cholerae outbreak in Malawi
-
Published:2024-07-26
Issue:1
Volume:15
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Chaguza ChrispinORCID, Chibwe InnocentORCID, Chaima David, Musicha PatrickORCID, Ndeketa Latif, Kasambara Watipaso, Mhango Chimwemwe, Mseka Upendo L., Bitilinyu-Bangoh Joseph, Mvula Bernard, Kipandula Wakisa, Bonongwe Patrick, Munthali Richard J.ORCID, Ngwira Selemani, Mwendera Chikondi A., Kalizang’oma Akuzike, Jambo Kondwani C.ORCID, Kambalame Dzinkambani, Kamng’ona Arox W.ORCID, Steele A. Duncan, Chauma-Mwale Annie, Hungerford DanielORCID, Kagoli Matthew, Nyaga Martin M.ORCID, Dube Queen, French Neil, Msefula Chisomo L., Cunliffe Nigel A., Jere Khuzwayo C.ORCID
Abstract
AbstractMalawi experienced its deadliest Vibrio cholerae (Vc) outbreak following devastating cyclones, with >58,000 cases and >1700 deaths reported between March 2022 and May 2023. Here, we use population genomics to investigate the attributes and origin of the Malawi 2022–2023 Vc outbreak isolates. Our results demonstrate the predominance of ST69 clone, also known as the seventh cholera pandemic El Tor (7PET) lineage, expressing O1 Ogawa (~ 80%) serotype followed by Inaba (~ 16%) and sporadic non-O1/non-7PET serogroups (~ 4%). Phylogenetic reconstruction revealed that the Malawi outbreak strains correspond to a recent importation from Asia into Africa (sublineage AFR15). These isolates harboured known antimicrobial resistance and virulence elements, notably the ICEGEN/ICEVchHai1/ICEVchind5 SXT/R391-like integrative conjugative elements and a CTXφ prophage with the ctxB7 genotype compared to historical Malawian Vc isolates. These data suggest that the devastating cyclones coupled with the recent importation of 7PET serogroup O1 strains, may explain the magnitude of the 2022–2023 cholera outbreak in Malawi.
Publisher
Springer Science and Business Media LLC
Reference106 articles.
1. Nelson, E. J. et al. Cholera transmission: the host, pathogen and bacteriophage dynamic. Nat. Rev. Microbiol. 7, 693–702 (2009). 2. Ali, M. et al. The global burden of cholera. Bull. World Health Organ. 90, 209–218A (2012). 3. Ali, M., Nelson, A. R., Lopez, A. L. & Sack, D. A. Updated global burden of cholera in endemic countries. PLoS Negl. Trop. Dis. 9, e0003832 (2015). 4. Khan, W. A. et al. Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139. Lancet 348, 296–300 (1996). 5. Greenough, W. B. 3rd, Gordon, R. S. Jr, Rosenberg, I. S., Davies, B. I. & Benenson, A. S. Tetracycline In The Treatment Of Cholera. Lancet 1, 355–357 (1964).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|